Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Melinta Therapeutics logo

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.35
$0.50
52-Week Range
N/A
Volume
N/A
Average Volume
713,628 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLNT Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
SWTX SpringWorks Therapeutics, Inc.
See More Headlines

MLNT Stock Analysis - Frequently Asked Questions

Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing the consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to the consensus estimate of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.

Shares of Melinta Therapeutics reverse split on the morning of Friday, February 22nd 2019.The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/12/2019
Today
7/09/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLNT
CIK
1461993
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$157.19 million
Net Margins
-393.39%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$96.43 million
Price / Cash Flow
N/A
Book Value
$16.96 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$6.88 million
Optionable
Optionable
Beta
4.16
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:MLNT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners